Published in Proteomics Weekly, June 10th, 2002
The company will investigate butamben as a supplement to opiate analgesia treatment for intractable cancer pain. Initiation of a full development program will depend on the outcome of the company's continuing market research and development assessment of the product.
In addition to licensing worldwide rights under two patents, the company has acquired preclinical and early clinical data. In these studies, a series of epidurally delivered butamben appeared to be highly selective in blocking...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.